Inhibikase Therapeutics (NASDAQ: IKT) insider transactions
In the twelve months to 10 November 2026, executives and directors of Inhibikase Therapeutics reported 0 open-market sales and 1 open-market purchase of 2,068,965 shares ($3.0m), by 1 person, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 30 July 2026 | Berman Dennis N | Director | Option exercise | +21,854 | $1.26 | 21,854 | Form 4 |
| 29 July 2026 | RA Capital Healthcare Fund LP | — | Other | −18,030,000 | — | 6,970,000 | Form 4 |
| 21 February 2026 | Munshi Amit | Director | Returned to the company | −19,089 | — | 38,176 | Form 4 |
| 21 February 2026 | Cabell Christopher | President & Head of R&D | Returned to the company | −338,282 | — | 676,564 | Form 4 |
| 21 February 2026 | Aurentz Vincent | Director | Returned to the company | −255,299 | — | 510,596 | Form 4 |
| 21 November 2025 | Sands Frank M. | — | Open-market purchase | +2,068,965 | $1.45 | 13,018,965 | Form 4 |
| 21 February 2025 | Munshi Amit | Director | Grant or award | +57,265 | — | 57,265 | Form 4 |
| 21 October 2024 | Munshi Amit | Director | Open-market purchase | +365,000 | $1.37 | 365,000 | Form 4 |
| 21 October 2024 | Kush Arvind | Director | Open-market purchase | +145,000 | $1.37 | 145,000 | Form 4 |
| 21 October 2024 | Bellini Roberto | Director | Open-market purchase | +1,460,000 | $1.37 | 1,460,000 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Inhibikase Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.